• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Immunome, Inc. - Common Stock (NQ:IMNM)

19.96 +0.56 (+2.89%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,301,513
Open 19.45
Bid (Size) 19.29 (100)
Ask (Size) 19.96 (3,000)
Prev. Close 19.40
Today's Range 19.35 - 20.44
52wk Range 7.960 - 27.65
Shares Outstanding 87,012,328
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-1617, a Potential First-in-Class ADC, in Patients with Advanced Solid Tumors
June 11, 2026
From Immunome, Inc.
Via Business Wire
News headline image
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 04, 2026
From Immunome, Inc.
Via Business Wire

Performance

YTD
-4.1%
-4.1%
1 Month
-8.9%
-8.9%
3 Month
-2.2%
-2.2%
6 Month
-8.1%
-8.1%
1 Year
+130.0%
+130.0%

More News

Read More
News headline image
Immunome Announces Detailed Phase 3 RINGSIDE Data for Varegacestat in Adults with Progressing Desmoid Tumors at the 2026 ASCO Annual Meeting
May 30, 2026
From Immunome, Inc.
Via Business Wire
News headline image
Immunome to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
May 27, 2026
From Immunome, Inc.
Via Business Wire
News headline image
Immunome Reports First Quarter 2026 Financial Results and Provides Business Update
May 12, 2026
From Immunome, Inc.
Via Business Wire
News headline image
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 05, 2026
From Immunome, Inc.
Via Business Wire
News headline image
Immunome Announces Submission of New Drug Application to U.S. FDA for Varegacestat for the Treatment of Adults with Desmoid Tumors
April 29, 2026
From Immunome, Inc.
Via Business Wire
News headline image
Immunome Announces Oral Presentation of Phase 3 RINGSIDE Data at 2026 ASCO Annual Meeting
April 21, 2026
From Immunome, Inc.
Via Business Wire
News headline image
Immunome's Chief Scientist Trimmed His Stake. A Planned FDA Submission Tells You More ↗
April 04, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 02, 2026
From Immunome, Inc.
Via Business Wire
News headline image
ENAVATE's Zenas Bio Pharma add Is a Footnote — The Obexelimab Pipeline Is What to Watch ↗
March 21, 2026
Via The Motley Fool
News headline image
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 05, 2026
From Immunome, Inc.
Via Business Wire
News headline image
Investment Manager Fully Exits Immunome Stock in $37.3 Million Sale, According to Latest SEC Filing ↗
March 04, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Immunome Reports Full Year 2025 Financial Results and Provides Business Update
March 03, 2026
From Immunome, Inc.
Via Business Wire
News headline image
Immunome to Present at Upcoming Investor Conferences
February 23, 2026
From Immunome, Inc.
Via Business Wire
News headline image
Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million ↗
February 22, 2026
Via The Motley Fool
News headline image
Biotech-Focused Fund Adds $12 Million to Immunome Bet as Stock Surges 120% ↗
February 22, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Investor Slashes $70 Million From Zymeworks as Stock Jumps 60% in a Year ↗
February 22, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Biotech Investor Adds $3 Million to Krystal Biotech as Revenue Hits $389 Million in 2025 ↗
February 22, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Biotech Fund Doubles Down With $49 Million Scholar Rock Buy as Shares Climb 26% ↗
February 22, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 05, 2026
From Immunome, Inc.
Via Business Wire
News headline image
The $71 Billion Cancer Shift: Why The FDA Is Speeding Up
February 05, 2026
From Equity Insider
Via GlobeNewswire
News headline image
Immunome to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
February 04, 2026
From Immunome, Inc.
Via Business Wire
News headline image
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 08, 2026
From Immunome, Inc.
Via Business Wire
News headline image
Immunome to Present at 44th Annual J.P. Morgan Healthcare Conference
January 06, 2026
From Immunome, Inc.
Via Business Wire

Frequently Asked Questions

Is Immunome, Inc. - Common Stock publicly traded?
Yes, Immunome, Inc. - Common Stock is publicly traded.
What exchange does Immunome, Inc. - Common Stock trade on?
Immunome, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Immunome, Inc. - Common Stock?
The ticker symbol for Immunome, Inc. - Common Stock is IMNM on the Nasdaq Stock Market
What is the current price of Immunome, Inc. - Common Stock?
The current price of Immunome, Inc. - Common Stock is 19.96
When was Immunome, Inc. - Common Stock last traded?
The last trade of Immunome, Inc. - Common Stock was at 06/26/26 04:00 PM ET
What is the market capitalization of Immunome, Inc. - Common Stock?
The market capitalization of Immunome, Inc. - Common Stock is 1.74B
How many shares of Immunome, Inc. - Common Stock are outstanding?
Immunome, Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap